Canaccord Genuity Maintains Buy on Pulse Biosciences, Raises Price Target to $58
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $43 to $58.
Canaccord Genuity analyst William Plovanic maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and raises the price target from $43 to $58.